The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Open accessAbstract
Summary Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer. Methods In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 10¹¹ viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849. Findings Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths. Interpretation Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state. Funding FKD Therapies Oy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., Lotan, Y., Meeks, J. J., Michalski, J. M., Morgan, T. M., et al. (2017) · Journal of Urology · doi:10.1016/j.juro.2017.04.086 · Cited by 938
Self-citationThe Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
Cookson, M. S., Herr, H. W., Zhang, Z.-F., Soloway, S., Sogani, P. C., & Fair, W. R. (1997) · Journal of Urology · doi:10.1097/00005392-199707000-00017 · Cited by 549
Self-citationShore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3064 · Cited by 167
Self-citationSkinner, E. C., Goldman, B., Sakr, W. A., Petrylak, D. P., Lenz, H.-J., Lee, C. T., Wilson, S. S., Benson, M., Lerner, S. P., Tangen, C. M., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.031 · Cited by 161
Self-citationIntravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer
Shelley, M. D., Court, J. B., Kynaston, H., Wilt, T. J., Fish, R., & MASON, M. D. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001986 · Cited by 149
Robotic versus open radical cystectomy for bladder cancer in adults
Rai, B. P., Bondad, J., Vasdev, N., Adshead, J. M., Lane, T., Ahmed, K., Khan, M. S., Prokar Dasgupta, A., Guru, K. A., Chłosta, P. L., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011903.pub2 · Cited by 140
Barlow, L. J., McKiernan, J. M., & Benson, M. C. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.10.068 · Cited by 121
Benedict, W. F., Tao, Z., Kim, C.-S., Zhang, X., Zhou, J.-H., Adam, L., McConkey, D. J., Papageorgiou, A., Munsell, M. F., Philopena, J. M., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.027 · Cited by 93
Self-citationInterferon alfa in the treatment paradigm for non–muscle-invasive bladder cancer
Lamm, D. L., Brausi, M. A., O’Donnell, M. A., & Witjes, J. A. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.02.010 · Cited by 56
Self-citation
Cited by
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.08.010 · Cited by 1,615
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
Therapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B. P., Ravaud, A., Shariat, S. F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.012 · Cited by 555
Metadata
- Authors
- Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., Poch, M., Crispen, P. L., Steinberg, G. D., Schuckman, A. K., Downs, T. M., Svatek, R. S., Mashni, J., Lane, B. R., Guzzo, T. J., Bratslavsky, G., Karsh, L. I., Woods, M. E., Brown, G., Canter, D., Luchey, A., Lotan, Y., Krupski, T., Inman, B. A., Williams, M. B., Cookson, M. S., Keegan, K. A., Andriole, G. L., Sankin, A. I., Boyd, A., O'Donnell, M. A., Sawutz, D., Philipson, R., Coll, R., Narayan, V. M., Treasure, F. P., Yla-Herttuala, S., Parker, N. R., & Dinney, C. P. N.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 22
- Issue
- 1
- Pages
- 107-117
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3108799736
- Cited by
- 480
- References
- 12
- FWCI
- 36.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30540-4
- The paper
- Boorjian, S. A., Alemozaffar, M., Konety, B. R., Shore, N. D., Gomella, L. G., Kamat, A. M., Bivalacqua, T. J., Montgomery, J. S., Lerner, S. P., Busby, J. E., Poch, M., Crispen, P. L., Steinberg, G. D., Schuckman, A. K., Downs, T. M., Svatek, R. S., Mashni, J., Lane, B. R., Guzzo, T. J., . . . Dinney, C. P. N. (2021). Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30540-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.